Literature DB >> 22390624

Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome.

D Sousa1, I Justo, A Domínguez, A Manzur, C Izquierdo, L Ruiz, M Nebot, J-M Bayas, J-M Celorrio, W Varona, P Llinares, E Miguez, E Sánchez, J Carratalá.   

Abstract

The number of elderly patients in the community with immunosuppressive conditions has increased progressively over recent decades. We sought to determine the incidence, causative organisms and outcome of community-acquired pneumonia (CAP) occurring in immunocompromised older patients. We prospectively compared cases of CAP in immunocompromised and non-immunocompromised patients admitted to five public hospitals in three Spanish regions. Of 320 cases studied, 115 (36%) occurred in immunocompromised patients, including: solid or hematological malignancy (97), corticosteroids or other immunosuppressive drugs (44), solid organ or stem cell transplant (five), and other conditions (eight). The etiology was established in 44% of immunocompromised patients vs. 32% of non-immunocompromised patients (p 0.03). Streptococcus pneumoniae was the most common causative organism in both groups (29% vs. 21%; p 0.08), followed by Legionella pneumophila (3% vs. 6%; p 0.01). Gram-negative bacilli were more frequent among immunocompromised patients (5% vs. 0.5%; p <0.01), particularly Pseudomonas aeruginosa (3% vs. 0%; p 0.04). Nocardiosis was only observed in immunocompromised patients (two cases). Bacteremia occurred similarly in the two groups. No significant differences were found with respect to ICU admission (8%, in both groups) or the length of stay (12.5 vs. 10.4 days). The early (<48 h) (3.5 vs. 0.5%; p 0.04) and overall case-fatality rates (12% vs. 3%; p <0.01) were higher in immunocompromised patients. In conclusion, a substantial number of older patients hospitalized for CAP are immunocompromised. Although relatively uncommon, CAP due to gram-negative bacilli, including P. aeruginosa, is more frequent among these patients. CAP occurring in immunocompromised patients causes significant morbidity and mortality.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22390624     DOI: 10.1111/j.1469-0691.2012.03765.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  29 in total

1.  Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study.

Authors:  Zhong-Shu Kuang; Yi-Lin Yang; Wei Wei; Jian-Li Wang; Xiang-Yu Long; Ke-Yong Li; Chao-Yang Tong; Zhan Sun; Zhen-Ju Song
Journal:  World J Emerg Med       Date:  2020

2.  Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.

Authors:  Byung Ju Kang; Younsuck Koh; Chae-Man Lim; Jin Won Huh; Seunghee Baek; Myongja Han; Hyun-Suk Seo; Hee Jung Suh; Ga Jin Seo; Eun Young Kim; Sang-Bum Hong
Journal:  Intensive Care Med       Date:  2015-02-18       Impact factor: 17.440

3.  Decreased NLRP3 inflammasome expression in aged lung may contribute to increased susceptibility to secondary Streptococcus pneumoniae infection.

Authors:  Soo Jung Cho; Maria Plataki; Dana Mitzel; Gena Lowry; Kristen Rooney; Heather Stout-Delgado
Journal:  Exp Gerontol       Date:  2017-12-07       Impact factor: 4.032

4.  Age-enhanced endoplasmic reticulum stress contributes to increased Atg9A inhibition of STING-mediated IFN-β production during Streptococcus pneumoniae infection.

Authors:  Dana N Mitzel; Virginia Lowry; Anushree C Shirali; Yushi Liu; Heather W Stout-Delgado
Journal:  J Immunol       Date:  2014-03-26       Impact factor: 5.422

5.  NLRP3 inflammasome activation in aged macrophages is diminished during Streptococcus pneumoniae infection.

Authors:  Soo Jung Cho; Kristen Rooney; Augustine M K Choi; Heather W Stout-Delgado
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

Review 6.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

7.  Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance.

Authors:  Oriol Sibila; Elena Laserna; Eric M Mortensen; Antonio Anzueto; Marcos I Restrepo
Journal:  Respir Care       Date:  2013-01-23       Impact factor: 2.258

8.  Burden of Pneumonia-Associated Hospitalizations: United States, 2001-2014.

Authors:  Brandon H Hayes; Dana L Haberling; Jordan L Kennedy; Jay K Varma; Alicia M Fry; Neil M Vora
Journal:  Chest       Date:  2017-10-07       Impact factor: 9.410

9.  Induction of Specific Humoral Immune Response in Mice against a Pseudomonas aeruginosa Chimeric PilQ/PilA Protein.

Authors:  Mehrdad Gholami; Alireza Salimi Chirani; Reza Falak; Mona Moshiri; Shabnam Razavi; Gholamreza Irajian
Journal:  Rep Biochem Mol Biol       Date:  2018-10

10.  Characteristics of viral pneumonia in non-HIV immunocompromised and immunocompetent patients: a retrospective cohort study.

Authors:  Lijuan Li; Steven H Hsu; Chunlei Wang; Binbin Li; Lingxiao Sun; Jinying Shi; Yali Ren; Jinxiang Wang; Xiaoqi Zhang; Jiangbo Liu
Journal:  BMC Infect Dis       Date:  2021-08-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.